T issue factor (TF) is an integral membrane protein, which binds to factor VII/VIIa and initiates the coagulation cascade. 1, 2 Expressed on the surface of lipid-laden monocytes, macrophages, and foam cells in human atherosclerotic lesions, TF acts as the major procoagulant for thrombus formation in acute coronary syndromes. 3, 4 The expression of TF in monocytes can be rapidly induced by lipopolysaccharide (LPS) and phorbol 12-myristate 13-acetate as well as by an inflammatory mediator found in atherosclerotic lesions, CD40L. 5, 6 TF activity of circulating monocytes appears controlled locally by its intrinsic inhibitor, TF pathway inhibitor (TFPI). 7 LPS-induced monocyte TF expression is regulated through a 56-bp promoter region (Ϫ227 through Ϫ172 bp) containing 2 activator protein-1 (AP-1) binding sites and a nuclear factor (NF)-B binding site, elements that bind c-fos/c-jun and c-Rel/p65 heterodimers, respectively. 8, 9 LPS-induced TF expression in cells of the monocyte lineage requires functional interaction between these transcription factors. 10 Although the clinical course of acute coronary events may be influenced by reduced monocyte/macrophage TF expression, 11 the mechanisms inhibiting TF expression in these cells remain largely unexplored. Animal studies suggest that a diet rich in polyunsaturated fatty acids (PUFAs) reduces TF expression in mononuclear cells, 12 whereas dietary intake of PUFAs in humans reduces TF activity in unstimulated and LPS-stimulated monocytes. 13 Thus, PUFAs seem to inhibit monocyte TF expression in vivo, although through unknown mechanisms. Interestingly, some of the PUFAs used in those studies (docosahexaenoic acid [DHA] and eicosatetraynoic acid [ETYA] ) are ligands for the peroxisome proliferatoractivated receptor-␣ (PPAR␣). 14 PPAR␣, as well as the other members of the PPAR family, PPAR␥ and PPAR␦, are ligand-activated transcription factors belonging to the nuclear hormone receptor superfamily. 15 PPAR␣ can be activated by PUFAs as well as lipid-lowering fibric acid derivatives, such as fenofibrate or WY14643. 16 Although prior work focused on PPAR␣ as a regulator of genes involved in lipid metabolism and fatty acid oxidation, 14 recent studies have highlighted its anti-inflammatory role in vascular cells. 17, 18 The effect of PPAR␣ activation on monocyte TF expression is unknown.
Given the clinical evidence that fibric acid drugs and PUFA-rich diets may reduce thrombotic complications of atherosclerosis, 12 the present study tested whether PPAR␣ activation limits inducible TF activity and expression in human cells of the monocytic lineage.
Methods

Cell Culture
Human monocytes isolated from freshly drawn blood of healthy volunteers by sequential Ficoll-Hypaque (Sigma) and Percoll (Sigma) gradient centrifugation were Ͼ85% pure. Monocyte-derived macrophages were obtained by culturing isolated human monocytes for 6 days (RPMI media, GIBCO; 5% human serum, Sigma; and 1% penicillin-streptomycin, GIBCO). The monocyte-like cell line THP-1, obtained from the American Tissue Culture Collection, was cultured as described before. 19 
Reverse Transcriptase-Polymerase Chain Reaction
Total RNA from freshly isolated monocytes, monocyte-derived macrophages, or THP-1 cells was isolated by the guanidinium thiocyanate-phenol-chloroform method (RNAzol, Tel-Test). Reverse transcriptase (RT)-polymerase chain reaction (PCR) for PPAR␣ and GAPDH was performed as described before. 20 
TF Activity Assay
For TF activity assays, monocytes, monocyte-derived macrophages, or THP-1 cells were pretreated with PPAR activators (PPAR␣ activators: ETYA, Sigma, and WY14643, Biomol; PPAR␥ activators: 15-deoxy _⌬12,14 -prostaglandin J 2 [15d-PGJ 2 ], Calbiochem, and BRL49653, SmithKline Beecham) for 30 minutes at the concentrations indicated and then LPS-stimulated (100 g/L for monocytes, 10 mg/L for THP-1 cells) for 5 hours. TF activity was determined by using a standard chromogenic assay (American Diagnostica). 6 
TNF-␣ ELISA
Monocytes or THP-1 cells (1ϫ10 6 cells/mL) were pretreated with the PPAR␣ activator WY14643 for 30 minutes before LPS stimulation at the concentrations indicated. Cells were cultured for 24 hours, and a tumor necrosis factor (TNF)-␣ ELISA (R&D Systems) was performed on cell-free supernatants by using a recombinant TNF-␣ standard curve.
Western Blot Analysis
For Western blot analysis of TF and TFPI expression, human monocytes or monocyte-derived macrophages were pretreated with WY14643 (30 minutes) at the concentrations indicated and stimulated with LPS (5 hours). Standard Western blot analysis on total cell lysates was performed by using mouse anti-human TF and mouse anti-human TFPI antibodies (monoclonal antibodies, American Diagnostica). Restaining with ␣-tubulin antibodies ensured equal loading of intact protein.
RNA Extraction and Northern Blot Analysis
For Northern blot experiments, cells were pretreated with the PPAR␣ or PPAR␥ activators for 30 minutes and then LPSstimulated (100 g/L, 2 hours). Five micrograms of total RNA was used in standard Northern blot analysis with the use of TF, TNF-␣, or GAPDH cDNA probes.
TF mRNA half-life was determined by stimulating monocytes with LPS for 2 hours before blocking transcription with actinomycin D (5 g/L). Cells then received WY14643 for the times indicated, and mRNA levels were compared with untreated cells.
Transient Transfection Assays
To investigate the effect of PPAR␣ activators on TF or TNF-␣ promoter activity, we transiently transfected THP-1 cells with TF promoter constructs containing the luciferase reporter [pTF(Ϫ2106)-LUC and pTNF-␣-LUC] as previously described. 9 To determine the effect of PPAR␣ on NF-B activation, p(B) 4 LUC, a luciferase reporter construct containing 4 copies of the TF-B site cloned upstream from the minimal simian virus 40 promoter 9 was transfected into THP-1 cells. Transfected cells were cultured for 46 hours before stimulation with LPS (10 mg/L) for 5 hours. Cells were harvested, and luciferase activity was measured as described before. 19 
Electrophoretic Mobility Shift Assay
Nuclear extracts of THP-1 cells were prepared by using standard procedures. 19 THP-1 cells were stimulated for 2 hours with LPS (10 g/mL) with or without WY14643 (10 or 100 mol/L) pretreatment before nuclear extract preparation. Oligonucleotides for the TFspecific NF-B site (5Ј-GTCCCGGAGTTTCCTACC-3Ј) or the prototypic site from the murine Ig gene were annealed with a complementary primer and radiolabeled with the use of [␣-32 P]dCTP (ICN) as described. 19 Protein-DNA complexes were separated from free DNA probe by electrophoresis (6% nondenaturing acrylamide gels/0.5ϫ Tris-borate-EDTA), and autoradiography was performed.
Assessment of Total Protein Synthesis
To determine the effects of WY14643 on total protein synthesis in human monocytes, cells were treated with LPS in the absence or presence of WY14643 in media containing [ Ci/mL) (Table) . After 5 hours, cells were harvested, and total protein synthesis in both lysates and supernatants was measured by counting radioactivity after cold trichloroacetic acid precipitation. 18 
Effects of WY14643 on Human Monocytes
LPS (10 g/L) LPS (10 g/L)ϩWY14643 (250 mol/L)
Statistical Analysis
Results of the experimental studies are reported as meanϮSEM or meanϮSD. Differences were analyzed by 1-way ANOVA followed by the Fisher least significant difference test. A value of PϽ0.05 was regarded as significant.
Results
Cells of Monocyte Lineage Express PPAR␣
To establish the expression of PPAR␣ in cells of the monocyte lineage used in our experiments, RT-PCR was performed. Freshly isolated human monocytes, monocytederived macrophages, and monocyte-like THP-1 cells all contained PPAR␣ mRNA as detected by a 276-bp RT-PCR product ( Figure 1 ).
PPAR␣ Activators Inhibit LPS-Induced TF Activity and TNF-␣ Expression in Human Monocytes
To determine the effect of PPAR␣ activation on LPS-induced TF activity in freshly isolated human monocytes, purified cells were pretreated for 30 minutes with the PPAR␣ activators WY14643 or ETYA at the concentrations indicated and then stimulated for 5 hours with LPS (100 g/L) before TF activity assays were performed. As expected, monocyte TF activity markedly increased in response to LPS stimulation. Pretreatment of cells with the PPAR␣ activators WY14643 ( Figure 2A ) and ETYA ( Figure 2B ) inhibited LPS-induced TF activity in a concentration-dependent manner, with a maximal reduction at 250 mol/L WY14643 or 30 mol/L ETYA to 43Ϯ8% (PϽ0.05, nϭ5) or 42Ϯ12% (PϽ0.05, nϭ3), respectively. Two different PPAR␥ activators, the naturally occurring ligand 15d-PGJ 2 and the antidiabetic agent BRL49653 (rosiglitazone), had no significant effect (PϭNS, nϭ3; Figure 2B ). PPAR␣ activators alone also had no effect on TF activity (data not shown). Cell viability in all conditions was Ͼ95%, as determined by trypan blue exclusion, suggesting that enhanced cell death is not responsible for these observations. In addition, WY14643 did not affect total protein synthesis in LPS-treated human monocytes, thus making toxic effects of PPAR␣ activators an unlikely explanation for our findings (Table) .
To investigate whether PPAR␣ alters other LPS-induced genes in human monocytes, we measured the effect of WY14643 on monocyte TNF-␣ protein secretion after LPS stimulation. Pretreatment of monocytes for 30 minutes with the PPAR␣ activator WY14643 significantly reduced LPS- induced TNF-␣ protein content in the supernatant ( Figure  2C) , with a maximal inhibition at 250 mol/L WY14643 (7696Ϯ449 pg/mL in LPS-treated cells versus 4490Ϯ197 pg/mL in LPS-and WY14643-treated cells, PϽ0.05; nϭ3). As previously reported, 21 2 PPAR␥ activators had no effect on LPS-induced TNF-␣ secretion.
PPAR␣ Activation Inhibits TF Protein Expression in Human Monocytes
To test whether the effect of PPAR␣ on TF activity corresponded to changes in TF protein levels, human monocytes were pretreated and stimulated as indicated, and Western Blot analysis was performed on total cell lysates. Stimulation of monocytes with LPS markedly increased TF protein expression, whereas 30-minute pretreatment with the PPAR␣ activator WY14643 reduced cellular TF protein content in a concentration-dependent manner (Figure 3, top) . In contrast, WY14643 did not reduce the expression of TFPI, the intrinsic inhibitor of TF activity (Figure 3, middle) .
PPAR␣, but Not PPAR␥, Activators Reduce LPS-Induced TF mRNA Levels in Human Monocytes
Northern blot analysis was used for the evaluation of a potential effect of PPAR␣ ligands at the mRNA level. Increased TF mRNA levels after a 2-hour stimulation of human monocytes with LPS (100 g/L) could be inhibited in a concentration-dependent manner by 30-minute pretreatment with the PPAR␣ activator WY14643 ( Figure 4A ). In contrast, pretreatment of monocytes with 2 different PPAR␥ activators, 15d-PGJ 2 (10 mol/L) and BRL49653 (10 mol/L), had no such effect ( Figure 4B ). In addition, WY14643 also decreased LPS-induced TNF-␣ mRNA expression ( Figure  4C ). Stimulation experiments in the presence of actinomycin D revealed that WY14643 did not significantly reduce TF mRNA half-life compared with the control condition ( Figure  4D ), indicating that PPAR␣ activators affect TF transcription but not mRNA stability.
WY14643 Reduces LPS-Induced TF Activity as Well as TF Protein and mRNA Expression in Monocyte-Derived Macrophages
To determine whether PPAR␣ activators had similar effects on TF activity in a more macrophage-like cell type, human monocyte-derived macrophages were used for stimulation experiments. As expected, these cells had higher baseline TF activity than did monocytes. Pretreatment of monocytederived macrophages with WY14643 reduced LPS-induced TF activity in a concentration-dependent manner with a maximal reduction at 100 mol/L to 40.3Ϯ7.6% (PϽ0.05 compared with LPS-stimulated cells, Figure 5A ). In addition, WY14643 also decreased LPS-induced TF protein ( Figure  5B ) and mRNA expression ( Figure 5C ) in these cells.
WY14643 Inhibits LPS-Induced TF Activity and TNF-␣ Protein Expression in Monocyte-Like THP-1 Cells
Because prior studies have successfully used monocytic THP-1 cells for investigating the regulation of TF expression, 9, 19 we used this cell line to study responsiveness to PPAR␣ agonism in anticipation of promoter analysis. Treatment of THP-1 cells with the PPAR␣ activator WY14643 decreased LPS-induced (10 mg/L) TF activity as well as TNF-␣ protein expression in a concentration-dependent fashion ( Figure 6 ). Maximal reduction of TF activity to 9.3Ϯ0.4% was achieved in cells treated with 100 mol/L WY14643 compared with LPS-stimulated cells. WY14643 decreased TNF-␣ protein expression from 1396Ϯ58 pg/mL in LPStreated cells to 144Ϯ8 pg/mL. These data indicate that the more readily transfectable monocyte-like THP-1 cells can be used to examine the effects of PPAR␣ activators on TF and TNF-␣.
PPAR␣ Activation Inhibits LPS-Induced TF and TNF-␣ Promoter Activity
THP-1 cells were transiently transfected with TF (pTF-LUC) or TNF-␣ (pTNF-LUC) promoter-reporter constructs to de- termine the effects of PPAR␣ activation on LPS-induced promoter activity. Stimulation of transfected cells with LPS (10 mg/L) increased TF promoter activity 7.8Ϯ1.8-fold, whereas 30-minute pretreatment with WY14643 reduced this increase to 3.3Ϯ1.1-fold ( Figure 7A ). Similar results were obtained when cells were transfected with the TNF-␣ promoter construct ( Figure 7B ). WY14643 alone had no effect on TF or TNF-␣ promoter activity.
PPAR␣ Activator WY14643 Reduces NF-B Activation but Does Not Inhibit DNA Binding of NF-B Transcription Factors p65/c-Rel
To assess the effect of PPAR␣ activation on LPS-induced NF-B activation, transient transfection experiments of reporter construct p(B) 4 LUC were performed. Stimulation of transfected cells with LPS (10 g/mL) induced a 50Ϯ5-fold increase in luciferase activity, which was reduced by 30% to 35Ϯ7-fold by WY14643 ( Figure 8A ). To investigate whether PPAR␣ activation inhibits binding of NF-B transcription factors to the TF promoter, we performed gel-shift analysis (electrophoretic mobility shift assay) with the use of oligonucleotides corresponding to the TF NF-B site. PPAR␣ activation did not inhibit LPS-induced nuclear translocation and DNA binding of the NF-B proteins to the TF promoter ( Figure 8B , left) nor did PPAR␣ activation alter binding of the NF-B proteins p50/p65, known to regulate monocyte TNF-␣ gene expression ( Figure 8B, right) .
Discussion
The present study demonstrates inhibition of LPS-induced TF and TNF-␣ expression by PPAR␣ activators in human monocytes and monocyte-derived macrophages. This effect is mediated through an inhibition of gene transcription, likely through changes in NF-B activation.
Human monocytes and macrophages express PPAR␣ as well as PPAR␥, [21] [22] [23] [24] although the amount of PPAR␥ compared with PPAR␣ may be lower in these cells. 24 In monocytes, PPAR␥ increases during differentiation, and its stimulation can inhibit the expression of genes implicated in atherosclerosis. [21] [22] [23] [24] However, we did not observe any effects of PPAR␥ activators on LPS-induced TF or TNF-␣ expression. These findings concur with previous reports showing that PPAR␥ activators inhibit phorbol 12-myristate 13-acetate but not LPS-induced TNF-␣ expression. 21 The lack of an effect by PPAR␥ activators on TF and TNF-␣ expression might result from lower levels of PPAR␥ in these cells or may indicate different PPAR subtype specificity. The PPAR␣ activators used in the present study, the fibric acid derivative WY14643 and the PUFA ETYA, likely inhibit TF expression via effects on PPAR␣. Both agents are known to be selective PPAR␣ activators. 16 Our experiments also revealed that lower concentrations of WY14643 yielded similar effects on TF activity and expression in monocyte-derived macrophages (Ϸ60% reduction at 100 mol/L WY14643) compared with freshly isolated monocytes (Ϸ57% reduction at 250 mol/L WY14643). This finding might reflect higher PPAR␣ expression levels in macrophages as previously described by Chinetti et al. 24 The reduction of TF activity, protein, and mRNA expression by PPAR␣ activators likely results from inhibition of gene transcription given its inhibition of LPS-induced TF promoter activity as well as the lack of an effect of WY14643 on TF mRNA half-life. The reduction of NF-B activation by PPAR␣ parallels our observation that PPAR␣ activators also decrease LPS-induced expression and promoter activity of TNF-␣, another NF-B-regulated gene. Gel-shift experiments suggest that PPAR␣ does not inhibit LPS-induced nuclear translocation or DNA binding of NF-B transcription factors to the TF promoter. Several models might account for the effect of PPAR␣ on functional NF-B activity independent of DNA-protein complex assembly. The NF-B proteins c-Rel/p65 and PPAR␣ have been shown to interact with several transcriptional coactivators, such as cAMP response element-binding protein or p300 25, 26 ; competition for such coactivators might inhibit NF-B signaling through a "sequestering" effect. Alternatively, a direct protein-protein interaction between PPAR␣ and c-Rel/p65 or between PPAR␣ and another coactivator might allow binding of NF-B proteins to the promoter but prevent functional activation of NF-B, as suggested previously. 27 Other mechanisms in addition to the Ϸ30% inhibition of NF-B activation suggested by the p(B) 4 LUC construct experiments might account for the effects of PPAR␣ on TF and TNF-␣. Because AP-1 is implicated in TF expression, its inhibition by PPAR␣ could also be involved. 27 Alternatively, the effects of PPAR␣ might engage a transcriptional repressor complex with corepressors such as N-CoR, as previously suggested in the context of the effects of retinoic acid receptor on TF expression. 28 Our findings that PPAR␣ activators reduce monocyte TF expression but not the expression of the intrinsic inhibitor of TF activity, TFPI, suggest a PPAR␣-mediated shift toward limiting a critical procoagulant in atherosclerosis, an effect with possible important in vivo relevance. Diets enriched in PPAR␣-activating PUFAs can limit the occurrence and course of acute coronary events, 29 and clinical studies with fibric acid derivatives demonstrate reduced cardiovascular events in patients with coronary heart disease. 30 The regulation by PPAR␣ of monocyte and macrophage TF expression may contribute to these reported benefits, a particular intriguing possibility given recent data from the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT), which demonstrated that fibric acid derivatives decrease cardiac events in coronary heart disease patients with low LDL levels despite only a modest HDL increase. 31 The observations reported in the present study may offer one molecular mechanism contributing to how PUFA-rich diets and fibrates might reduce acute coronary events.
